Last10K.com

Cellectis S.A. (CLLS) SEC Filing 6-K Foreign Issuer report for the period ending Thursday, March 7, 2019

Cellectis S.A.

HISTORY TOOLS
CIK: 1627281 Ticker: CLLS

View differences made from one to another to evaluate Cellectis S.A.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 6-K Foreign Issuer Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Cellectis S.A..

Continue

Assess how Cellectis S.A.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Cellectis S.A.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Material Contracts, Statements, Certifications & more

Cellectis S.A. provided additional information to their SEC Filing as exhibits

Exhibit 99.1: Additional Exhibits
Ticker: CLLS
CIK: 1627281
Form Type: 6-K Foreign Issuer Report
Accession Number: 0001157523-19-000555
Submitted to the SEC: Thu Mar 07 2019 4:32:47 PM EST
Accepted by the SEC: Thu Mar 07 2019
Period: Thursday, March 7, 2019
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/clls/0001157523-19-000555.htm